Table 3.

Odds ratios of top serum protein levels by patient and tumor clinicopathological features

				ADA			CAIX			CASP8			CD244			CD8A
Clinicopathological features		N	OR	95%CI	P value	OR	95%CI	P value	OR	95%CI	P value	OR	95%CI	P value	OR	95%CI	P value
Age	< 65	65	1			1			1			1			1
	≥ 65	71	0.52	0.26–1.03	0.086a	1.06	0.54–2.08	1.00a	0.94	0.48–1.85	1.00a	0.94	0.48–1.85	1.00a	0.59	0.30–1.16	0.17a
ECOG	0	75	1			1			1			1
	1	36	1.27	0.57–2.82	0.55b	1.14	0.51–2.53	0.75b	3.36	1.46–7.75	0.005b	0.83	0.37–1.84	0.65b	0.78	0.35–1.73	0.54b
	2	21	2.55	0.92–7.03	0.071b	3.18	1.11–9.10	0.031b	3.36	1.21–9.32	0.020b	0.33	0.12–0.95	0.039b	1.07	0.41–2.82	0.89b
NHG	I-II	68	1			1			1			1
	III	42	1.53	0.71–3.32	0.33a	1.06	0.49–2.29	1.00a	1.15	0.53–2.49	0.84a	0.81	0.37–1.75	0.7a	0.59	0.27–1.29	0.24a
PT tumor size	1	49	1			1			1			1
	2	46	1.88	0.83–4.25	0.13b	1.05	0.47–2.34	0.91b	1.03	0.46–2.31	0.94b	1.03	0.46–2.31	0.94b	1.23	0.55–2.75	0.62b
	3	17	1.40	0.46–4.27	0.55b	0.52	0.17–1.64	0.27b	1.09	0.36–3.30	0.88b	3.99	1.14–13.98	0.031b	1.38	0.46–4.17	0.57b
	4	17	2.90	0.92–9.13	0.070b	1.08	0.36–3.26	0.89b	2.25	0.72–7.06	0.16b	1.75	0.57–5.36	0.33b	2.25	0.72–7.06	0.16b
PT node status	Neg	39	1			1			1			1
	Pos	79	0.84	0.39–1.80	0.70a	0.65	0.30–1.40	0.33a	0.55	0.26–1.20	0.17a	1.62	0.75–3.53	0.24a	1.47	0.68–3.18	0.43a
MFI	0	28	1			1			1			1
	0–3	25	1.27	0.43–3.76	0.66b	1.73	0.58–5.16	0.33b	1.10	0.37–3.26	0.86b	1.78	0.59–5.36	0.31b	1.08	0.37–3.19	0.88b
	> 3	83	0.93	0.40–2.19	0.87b	1.07	0.46–2.53	0.87b	0.77	0.33–1.81	0.55b	0.84	0.36–1.99	0.70b	0.98	0.41–2.30	0.96b
Metastatic sites	< 3	96	1			1			1			1
	≥ 3	40	2.39	1.11–5.13	0.038a	1.33	0.63–2.79	0.57a	2.79	1.28–6.05	0.014a	1	0.48–2.09	1.00a	1.33	0.63–2.79	0.57a
Site of metastasis	Non-visceral	56	1			1			1			1
	Visceral	80	1.28	0.64–2.53	0.60a	2.37	1.18–4.78	0.023a	1.63	0.82–3.24	0.22a	1.13	0.57–2.24	0.86a	1.13	0.57–2.24	0.86a
First line	Endocrine	55	1			1			1			1
treatment	Chemotherapy	60	3.08	1.44–6.62	0.004b	1.98	0.94–4.17	0.072b	2.14	1.01–4.52	0.047b	0.72	0.35–1.51	0.39b	1.19	0.57–2.47	0.65b
	HER2 targeted	13	4.63	1.25–17.07	0.021b	2.59	0.75–8.98	0.13b	2.80	0.81–9.73	0.11b	0.66	0.20–2.23	0.51b	0.46	0.13–1.68	0.24b
CTC	< 5	65	1			1			1			1
	≥ 5	69	3.44	1.69–7.00	0.001a	1.27	0.65–2.51	0.50a	1.62	0.82–3.21	0.17a	0.62	0.31–1.22	0.17a	1.20	0.61–2.36	0.73a
CTC clusters	Neg	108	1			1			1			1
	Pos	26	4.49	1.67–12.08	0.002a	2.27	0.93–5.55	0.082a	2.27	0.93–5.55	0.082a	0.54	0.22–1.29	0.19a	1.21	0.51–2.86	0.83a
PAM50 subtype	Luminal A	39	1			1			1			1
	Luminal B	41	6.25	2.35–16.55	0.0002b	1.13	0.46–2.78	0.78b	2.56	1.03–6.33	0.043b	1.83	0.75–4.44	0.18b	0.90	0.37–2.17	0.81b
	HER2 enriched	13	6.53	1.64–25.93	0.0077b	3.60	0.94–13.79	0.062b	4.50	1.16–17.41	0.029b	1.11	0.31–3.91	0.87b	0.38	0.10–1.45	0.16b
	Basal like	14	2.90	0.81–10.33	0.10b	4.00	1.06–15.08	0.041b	3.60	1.00–12.95	0.050b	1.29	0.38–4.40	0.68b	0.86	0.25–2.91	0.81b

				CSF1			FasL			IL-6			IL-8			IL-10
Clinicopathological features		N	OR	95%CI	P value	OR	95%CI	P value	OR	95%CI	P value	OR	95%CI	P value	OR	95%CI	P value
Age	< 65	65	1			1			1			1			1
	≥ 65	71	1.34	0.68–2.64	0.49a	0.66	0.34–1.30	0.30a	1.19	0.61–2.34	0.73a	0.84	0.43–1.64	0.73a	1.19	0.61–2.34	0.73a
ECOG	0	75	1			1			1			1			1
	1	36	3.77	1.63–8.74	0.002b	0.42	0.19–0.96	0.039b	2.97	1.30–6.78	0.010b	2.50	1.11–5.64	0.027b	1.68	0.75–3.74	0.20b
	2	21	4.71	1.63–13.59	0.004b	0.33	0.12–0.92	0.034b	2.73	1.01–7.40	0.049b	19.00	4.10–88.10	< 0.001b	2.69	0.97–7.42	0.057b
NHG	I-II	68	1			1			1			1			1
	III	42	1.24	0.57–2.67	0.70a	0.63	0.29–1.36	0.33a	1.39	0.64–3.02	0.44a	1.45	0.67–3.13	0.43a	1.02	0.47–2.21	1.00a
PT tumor size	1	49	1			1			1			1			1
	2	46	1.59	0.71–3.57	0.26b	1.04	0.46–2.32	0.93b	1.46	0.65–3.27	0.36b	1.46	0.65–3.28	0.36b	0.95	0.42–2.13	0.90b
	3	17	0.93	0.31–2.86	0.90b	2.71	0.83–8.87	0.099b	0.93	0.31–2.86	0.90b	1.09	0.36–3.30	0.88b	1.62	0.53–4.94	0.40b
	4	17	2.44	0.78–7.68	0.13b	1.27	0.42–3.84	0.67b	3.20	0.98–10.49	0.055b	1.38	0.46–4.17	0.57b	1.62	0.53–4.94	0.40b
PT node status	Neg	39	1			1			1			1			1
	Pos	79	0.88	0.41–1.90	0.85a	1.2	0.55–2.58	0.7a	1.03	0.48–2.22	1.00a	0.76	0.35–1.63	0.56a	0.80	0.37–1.72	0.70a
MFI	0	28	1			1			1			1			1
	0–3	25	1.50	0.50–4.46	0.47b	1.73	0.58–5.16	0.33b	0.82	0.28–2.46	0.73b	1.10	0.37–3.26	0.86b	0.58	0.19–1.72	0.33b
	> 3	83	0.89	0.38–2.09	0.78b	1.07	0.46–2.53	0.87b	0.52	0.22–1.25	0.14b	0.77	0.33–1.81	0.55b	0.93	0.40–2.20	0.87b
Metastatic sites	< 3	96	1			1			1			1			1
	≥ 3	40	2.79	1.28–6.05	0.014a	0.87	0.42–1.82	0.85a	3.27	1.49–7.19	0.004a	2.79	1.28–6.05	0.014a	2.39	1.11–5.13	0.038a
Site of metastasis	Non-visceral	56	1			1			1			1			1
	Visceral	80	2.09	1.04–4.19	0.055a	1.28	0.64–2.53	0.60a	2.70	1.33–5.47	0.009a	1.85	0.92–3.68	0.12a	1.63	0.82–3.24	0.22a
First line	Endocrine	55	1			1			1			1			1
treatment	Chemotherapy	60	1.59	0.76–3.33	0.22b	0.71	0.34–1.49	0.37b	1.85	0.88–3.89	0.11b	1.85	0.88–3.89	0.11b	1.71	0.82–3.60	0.15b
	HER2 targeted	13	1.62	0.48–5.47	0.44b	0.2	0.049–0.81	0.024b	1.89	0.56–6.39	0.31b	1.89	0.56–6.39	0.31b	1.29	0.38–4.34	0.69b
CTC	< 5	65	1			1			1			1			1
	≥ 5	69	1.83	0.92–3.63	0.088a	1	0.51–1.97	1.00a	1.44	0.73–2.84	0.31a	2.07	1.04–4.12	0.04a	1.52	0.77–3.01	0.30a
CTC clusters	Neg	108	1			1			1			1			1
	Pos	26	1.52	0.64–3.62	0.39a	0.8	0.34–1.88	0.67a	1.04	0.44–2.44	1.00a	8	2.58–24.82	< 0.001a	4.33	1.61–11.63	0.004a
PAM50 subtype	Luminal A	39	1			1			1			1			1
	Luminal B	41	2.02	0.83–4.95	0.12b	1.34	0.56–3.24	0.51b	1.23	0.51–2.97	0.64b	2.28	0.93–5.61	0.072b	1.11	0.46–2.67	0.81b
	HER2 enriched	13	1.00	0.28–3.52	1.00b	0.47	0.12–1.78	0.27b	1.51	0.43–5.33	0.52b	4.02	1.04–15.46	0.043b	1.36	0.39–4.79	0.63b
	Basal like	14	0.88	0.26–3.00	0.83b	0.79	0.23–2.70	0.71b	2.33	0.66–8.24	0.19b	4.46	1.18–16.90	0.028b	2.92	0.78–10.91	0.11b

				MCP2			MUC16			TNFRSF4
Clinicopathological features		N	OR	95%CI	P value	OR	95%CI	P value	OR	95%CI	P value
Age	< 65	65	1			1			1
	≥ 65	71	1.34	0.68–2.64	0.49a	1.19	0.61–2.34	0.73a	1.06	0.54–2.08	1.00a
ECOG	0	75	1			1			1
	1	36	1.60	0.72–3.57	0.25b	1.77	0.80–3.96	0.16b	1.68	0.75–3.74	0.20b
	2	21	1.04	0.39–2.74	0.94b	5.08	1.68–15.35	0.004b	2.18	0.81–5.89	0.12b
NHG	I-II	68	1			1			1
	III	42	0.94	0.44–2.04	1.00a	0.96	0.45–2.08	1.00a	1.06	0.49–2.29	1.00a
PT tumor size	1	49	1			1			1
	2	46	0.75	0.33–1.67	0.48b	0.88	0.39–1.96	0.75b	2.05	0.91–4.65	0.085b
	3	17	0.72	0.24–2.19	0.57b	1.49	0.49–4.55	0.49b	1.78	0.58–5.40	0.31b
	4	17	0.92	0.30–2.77	0.88b	1.17	0.39–3.54	0.78b	2.90	0.92–9.13	0.070b
PT node status	Neg	39	1			1			1
	Pos	79	1.39	0.65–3.01	0.44a	1.26	0.58–2.72	0.70a	1.33	0.61–2.87	0.056a
MFI	0	28	1			1			1
	0–3	25	1.07	0.36–3.14	0.91b	1.73	0.58–5.16	0.33b	1.18	0.50–2.79	0.70b
	> 3	83	1.24	0.53–2.93	0.62b	1.07	0.46–2.53	0.87b	0.95	0.39–2.31	0.90b
Metastatic sites	< 3	96	1			1			1
	≥ 3	40	2.39	1.11–5.13	0.038a	3.27	1.49–7.19	0.004a	2.79	1.28–6.05	0.014a
Site of metastasis	Non-visceral	56	1			1			1
	Visceral	80	2.37	1.18–4.78	0.023a	2.09	1.04–4.19	0.055a	1.63	0.82–3.24	0.22a
First line	Endocrine	55	1			1			1
treatment	Chemotherapy	60	0.83	0.40–1.74	0.63b	2.17	1.02–4.60	0.044b	1.58	0.76–3.30	0.22b
	HER2 targeted	13	0.37	0.10–1.35	0.13b	4.26	1.16–15.68	0.029b	0.81	0.23–2.78	0.74b
CTC	< 5	65	1			1			1
	≥ 5	69	0.74	0.38–1.46	0.49a	3.44	1.69–7.00	< 0.001a	1.52	0.77–3.01	0.30a
CTC clusters	Neg	108	1			1			1
	Pos	26	0.56	0.23–1.34	0.28a	5.88	2.06–16.76	< 0.001a	3.39	1.32–8.74	0.015a
PAM50 subtype	Luminal A	39	1			1			1
	Luminal B	41	0.99	0.41–2.39	0.99b	1.84	0.76–4.46	0.18b	1.83	0.75–4.44	0.18b
	HER2 enriched	13	0.54	0.15–1.93	0.34b	1.68	0.47–5.93	0.42b	0.81	0.22–2.92	0.75b
	Basal like	14	0.86	0.25–2.91	0.81b	3.59	0.96–13.50	0.058b	2.33	0.66–8.24	0.19b

CTC circulating tumor cells; ECOG Eastern Cooperative Oncology Group; HER2 human epidermal growth factor receptor 2; MFI metastasis-free interval; NHG Nottingham histological grade; PT primary tumor

^aP value from Fisher’s exact test

^bP value from logistic regression